NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development

Impact · against what's priced in

ELAB shares may see a modest lift as the company provides concrete preclinical evidence that EL-32 can preserve lean mass when paired with semaglutide. This moves the asset from a conceptual discovery phase toward a formal development strategy and potential IND filing.

ELAB+0.40

No priced-in read yet